secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akari Therapeutics Plc (AKTX)
CIK:        0001541157
Form:       8-K
Filed at:   2024-05-16T23:59:59+00:00
Accession:  0000950170-24-060806
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akari Therapeutics Q1 net loss $5.6M; cash $1.3M; merges with Peak Bio, cuts 67% workforce
--------------------------------------------------------------------------------

- Q1 net loss $5.6M vs net income $1.0M in Q1 2023; adjusted net loss $6.2M excluding warrant gains.
- Cash $1.3M as of March 31, 2024; issued $1M in unsecured convertible notes from CEO and Chairman.
- Entered all-stock merger with Peak Bio, expected close Q3 2024; combined company will trade as AKTX.
- Appointed Samir R. Patel as interim CEO; suspended HSCT-TMA program.
- Reduced workforce by ~67% as part of restructuring to cut costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1541157/000095017024060806/0000950170-24-060806-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1541157/000095017024060806/aktx-20240516.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-060806

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer